



Cancers Precision Immunotherapy

Guest Editor:

Prof. Dr. Razelle Kurzrock

Froedtert & The Medical College
of Wisconsin Clinical Cancer
Center, Milwaukee, WI 53226, USA

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Precision immunotherapy refers to the field of matching immune therapies to a tumor's immunomic landscape in order for that tumor to be treated with immunotherapy in a "precise" manner. Because the immune environment of each tumor may be distinct, treating precisely appears to require a personalized/individualized immunotherapy approach. There are many innovative ways to address the immune deficits that allow tumors to grow. Some of the new and powerful tools in the therapeutic armamentarium include CAR T-cells, bispecific antibodies, personalized vaccines, immune checkpoint inhibitors and immune stimulatory molecules. Interrogating the tumor immunogram and matching the patient to the compounds that are most likely to reactivate the immune system and permit it to eliminate cancer cells requires multiple advanced molecular technologies. Even so, precision immunotherapy has shown a remarkable ability to eradicate even advanced malignancies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)